Cancer news covering oncology trials, treatment advances, screening guidelines, epidemiology, and patient outcomes.
Researchers analyzing nearly 2,700 patients found that tumor testing can reveal inherited genetic alterations missed by standard diagnostics. About one in ten solid cancer cases carried these hereditary risks, with roughly a third of predisposition syndromes previously undetected, impacting family health screening protocols.
The FDA granted accelerated approval for Johnson & Johnson's Rybrevant Faspro for specific head and neck cancers, marking the first use of the amivantamab-based drug outside lung cancer treatment. The decision relied on tumor response data from the Phase 1b/2 OrigAMI-4 trial.
A federal study links elevated levels of PFOA and PFOS in women's blood to increased rates of aggressive, ER-negative breast cancer. Researchers suggest these persistent chemicals may affect cancer risk through non-hormonal pathways, prompting Health Secretary Robert F. Kennedy Jr. to call for clearer answers on environmental health impacts.
The article reports on scientific advancements where researchers are engineering cancer cells to produce destructive chemicals internally. It suggests this approach could replace systemic drug flooding, offering a more targeted treatment method for tumors while potentially reducing side effects associated with traditional chemotherapy.
The Seattle Times reports that experts urge maintaining discussion of breast cancer risks as hormone therapy usage rises among menopausal women. Despite removed black box warnings, scientists argue that individual risk-benefit assessments must still account for potential oncological dangers associated with systemic treatments.
Dr. Keith Roach contends that next-generation genetic sequencing (NGS) can significantly reshape cancer treatment plans for specific malignancies like lung and prostate cancers. He suggests that while NGS offers precision therapy benefits, it is not universally appropriate due to high costs, time delays, and the need for patients to be healthy enough to tolerate resulting treatments.
Cancer diagnoses in England reached a record high of more than 1,000 people per day in 2024, totaling 373,574 new cases. NHS figures show an increase of 11,833 diagnoses compared to 2023, with prostate cancer remaining the most common type, yet the NHS continues to miss key performance targets for timely diagnosis and treatment.
A medical expert argues that genetic testing via next-generation sequencing (NGS) is a critical tool for cancer patients, potentially altering treatment plans for 10 to 20 percent of cases. The article supports NGS for advanced lung, prostate, ovarian, bile duct, and colorectal cancers, noting that while costs and time are barriers, precision therapies offer significant benefits for eligible patients.
Dr. Keith Roach argues that genetic testing for advanced cancers like lung and prostate cancer can significantly alter treatment plans by identifying specific mutations. He contends that while clinical benefits are strong, widespread adoption is hindered by high costs ranging from $600 to $5,000 and delays in receiving results.
Dr. Keith Roach argues that genetic testing for cancer is beneficial for patients eligible for targeted therapies, particularly in advanced lung, prostate, ovarian, bile duct, and colorectal cancers. He notes that while costs and time are downsides, current data shows treatment changes for 10-20% of patients, with expectations of greater future benefits as precision medicine evolves.